AOD-9604

AOD-9604

$90.00

AOD-9604 is a synthetic peptide fragment derived from human growth hormone (HGH), specifically the C-terminal region (amino acids 176–191). Designed for research into metabolic functions, this peptide has attracted scientific attention due to its potential role in lipid metabolism and fat mobilization in non-human models.

Unlike full-length HGH, AOD-9604 does not appear to influence blood glucose levels or promote IGF-1 release in tested environments, making it a unique candidate for studies focused on selective metabolic pathways. Research has indicated that AOD-9604 may mimic the fat-reducing activity of HGH without its associated anabolic or growth-inducing effects.

In lab settings, AOD-9604 has been used to study lipolysis (breakdown of fat) and lipogenesis inhibition in adipose tissue. Its structure allows it to interact with beta-adrenergic receptors in a way that may promote fat breakdown, making it an ideal subject in obesity, metabolism, and energy balance research.

0% 1 - 4 $90.00
10% 5 - 9 $81.00
20% 10 + $72.00
  • Free shipping on orders over $200
  • Discounts: Calculated in cart.

Description

AOD-9604 is a synthetic peptide analog derived from the 176-191 amino acid fragment of human growth hormone (HGH). This specific region has been identified as critical for the fat-metabolizing effects of HGH, and AOD-9604 was engineered to isolate these actions while avoiding the broader hormonal effects associated with the complete HGH molecule.

Structurally, AOD-9604 differs from full-length HGH in that it does not activate growth-related pathways, such as those involving IGF-1 (insulin-like growth factor 1). This makes it an attractive compound for researchers studying targeted fat metabolism and body composition without systemic growth stimulation. In animal and in vitro studies, AOD-9604 has demonstrated activity in enhancing lipolysis and inhibiting lipogenesis, particularly in white adipose tissue.

The peptide is believed to work by mimicking the way HGH regulates fat breakdown without significantly affecting carbohydrate metabolism. It appears to act on beta-adrenergic receptors or similar targets involved in lipid metabolism. Importantly, AOD-9604 does not exhibit the diabetogenic or insulin-antagonistic effects seen with full-length growth hormone, which adds to its appeal in obesity and metabolic syndrome research models.

AOD-9604 has also been explored for its potential benefits in cartilage repair. Preliminary studies have indicated that it may stimulate chondrocyte activity and support the regeneration of joint tissue, which opens further research avenues in orthopedic and regenerative medicine.

The peptide has been tested for stability and safety in a variety of laboratory settings, and its favorable pharmacokinetic profile allows for easy integration into long-term animal studies. AOD-9604 has shown low systemic toxicity and does not seem to significantly affect normal endocrine function in test subjects.

Given its fat-specific action and lack of systemic hormonal effects, AOD-9604 is frequently used in metabolic studies, especially those focused on non-anabolic modulation of body fat and energy utilization. Its unique properties provide a valuable tool for scientists researching targeted metabolic pathways without the complications of full hormone supplementation.

For research use only. Not for human or veterinary use.

Product Data

  • Chemical Name: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
  • Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
  • CAS Number: 221231-10-3
  • Molecular Formula: C78H123N23O23S2
  • Molecular Weight: 1815.1 g/mol

Research

AOD-9604 has been at the center of research focused on selective fat metabolism. One of the earliest findings related to this peptide was its ability to mimic the lipolytic activity of human growth hormone (HGH), particularly through the 176–191 fragment, which was found to be responsible for HGH’s fat-burning properties.

In a series of in vitro studies, AOD-9604 demonstrated increased fat breakdown in isolated adipose tissue without triggering anabolic effects. These studies supported the hypothesis that it could selectively enhance lipolysis while leaving muscle and organ growth unaffected. Unlike HGH, which broadly affects IGF-1 levels and glucose metabolism, AOD-9604 exhibited no significant impact on insulin sensitivity or blood sugar levels, reducing the risk of diabetogenic side effects in test models.

Research also suggests that AOD-9604 may suppress the formation of new fat cells by inhibiting lipogenesis. In rodent models, the peptide reduced body fat accumulation even in the presence of a high-calorie diet. These findings have made AOD-9604 an appealing compound for studying mechanisms related to energy balance, diet-induced obesity, and metabolic rate modulation.

Beyond metabolic effects, studies have shown promise for AOD-9604 in joint and cartilage research. In cell cultures and animal models, the peptide has been observed to enhance chondrocyte proliferation and stimulate proteoglycan synthesis, indicating potential for tissue repair applications. Although further studies are needed, these findings provide a basis for its use in regenerative research, particularly concerning joint damage and osteoarthritis models.

The peptide has also been evaluated in preclinical safety studies, where it showed a favorable profile. It demonstrated high tolerability, low toxicity, and minimal systemic hormonal interference, making it a candidate for long-term experimental protocols in animals.

Additionally, the peptide’s selectivity offers a model for studying non-endocrine fat regulation mechanisms, which is a promising field for obesity and metabolic disorder research. Researchers are especially interested in its ability to operate independently of IGF-1 pathways, offering new insights into targeted lipid modulation.

In summary, AOD-9604 continues to gain relevance in scientific investigations into fat metabolism, cartilage health, and metabolic regulation. Its structural specificity and minimal endocrine disruption make it a useful research tool for laboratories studying non-anabolic therapeutic pathways in metabolic disorders and musculoskeletal conditions.

This compound is intended strictly for research purposes only. Not intended for human or animal consumption.

  1. F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000.
  2. H. Stier, E. Vos, and D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., vol. 3, no. 1–2, pp. 7-15–15, Apr. 2013. [Journal of Endocrinology & Metabolism]
  3. “Obesity drug codenamed AOD9604 highly successful in trials,” News-Medical.net, 16-Dec-2004. [Online]. Available: [Accessed: 24-May-2019].
  4. M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001.
  5. D. R. Kwon and G. Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, no. 4, pp. 426–432, Jul. 2015.
  6. M. D. Jensen, “Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors,” Obes. Silver Spring Md, vol. 14 Suppl 3, pp. 143S-149S, Jun. 2006.

Related products

Scroll to Top
0